ASST Grande Ospedale Metropolitano Niguarda
- Address
- lock Available on a paid plan
Hematology and Lymphoma Research
At ASST Grande Ospedale Metropolitano Niguarda, a major focus is hematologic malignancies, with studies in classical Hodgkin lymphoma, non-Hodgkin lymphoma, follicular lymphoma, marginal zone lymphoma, chronic lymphocytic leukemia, and other rare B-cell cancers. These trials are designed to test new treatment combinations, improve disease control, and evaluate better options for patients whose disease has returned or is difficult to treat.
- Classical Hodgkin lymphoma and pediatric/young adult lymphomas are being studied to assess treatment response and safety of newer immunotherapy approaches.
- Follicular lymphoma, marginal zone lymphoma, and related indolent lymphomas are included in studies comparing targeted therapies and combination regimens.
- Chronic lymphocytic leukemia, Waldenström macroglobulinemia, hairy cell leukemia, and other rare B-cell disorders are being investigated to improve outcomes in relapsed or previously untreated disease.
This work reflects a strong Clinical Trial Unit expertise in blood cancers, with attention to both standard and innovative treatment strategies.
Cardiovascular Disease Prevention and Treatment
The site is active in cardiovascular diseases, including atherosclerotic cardiovascular disease, atrial fibrillation, heart failure, and stroke prevention. Research here often focuses on whether new medicines can lower the risk of major cardiac and vascular events, improve long-term protection, and offer alternatives for patients who cannot use standard therapies.
- Atherosclerotic cardiovascular disease and high-risk prevention are being studied to reduce heart attack and stroke risk.
- Atrial fibrillation trials are evaluating safer ways to prevent embolic events.
- Chronic heart failure and broader cardiovascular outcomes research aim to improve survival and reduce hospitalizations.
Several studies at ASST Grande Ospedale Metropolitano Niguarda also examine cholesterol and triglyceride disorders, linking prevention with everyday cardiovascular care.
Oncology Across Solid Tumors
A broad neoplasms portfolio covers colorectal cancer, lung cancer, ovarian cancer, endometrial cancer, pancreatic cancer, biliary tract cancer, and head and neck cancer. The main goal is to evaluate new immunotherapy, targeted therapy, and peri-operative treatment approaches that may improve response rates, delay progression, or make surgery more effective.
- Colorectal cancer studies include both resectable and metastatic disease, with interest in pre-operative and post-treatment strategies.
- Non-small cell lung cancer, ovarian cancer, and head and neck squamous cell carcinoma are being explored with immunotherapy-based combinations.
- Biliary tract, pancreatic, and endometrial cancers are included in trials seeking better control of advanced or recurrent disease.
This oncology research supports personalized treatment selection and more effective care for patients with difficult-to-treat solid tumors.
Liver, Digestive, and Metabolic Disorders
The research program also includes digestive system diseases and nutritional and metabolic diseases, such as Crohn's disease, primary biliary cholangitis, portal hypertension, cirrhosis, type 2 diabetes, and lipid disorders. These trials are aimed at improving symptom control, slowing disease complications, and testing therapies that may better manage long-term metabolic and liver-related conditions.
- Crohn's disease research focuses on maintaining disease control in patients who respond to treatment.
- Primary biliary cholangitis and cirrhosis with portal hypertension studies are evaluating options for itching and liver pressure-related complications.
- Type 2 diabetes, hypercholesterolemia, and hypertriglyceridemia trials are looking at better metabolic management and cardiovascular risk reduction.
The clinical work at ASST Grande Ospedale Metropolitano Niguarda connects liver care, gastroenterology, and metabolic medicine in a practical hospital setting.
Neurology, Eye Care, and Public Health Studies
Additional research spans nervous system diseases, eye diseases, and environment and public health. This includes trials in stroke, intracerebral hemorrhage, dyskinesia due to cerebral palsy, and pediatric eye anesthesia, along with studies on infectious disease and critically ill patients. The purpose is to improve everyday clinical care, support recovery, and assess practical treatment approaches in both adults and children.
- Stroke and intracerebral hemorrhage research is examining ways to improve urgent care and early outcomes.
- Dyskinesia due to cerebral palsy studies are focused on symptom relief and better movement control.
- Eye disease research includes pediatric procedures designed to make clinical exams more comfortable and effective.
The site also contributes to infectious disease and critical care research, including studies related to mpox and emergency airway management.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 22 therapeutic areas and 15 of 500 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 483 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 115 by active trials.
- 1AstraZeneca AB19active
lock +114 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1AstraZeneca AB29trials
lock +62 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 566 other sites in Italy
Therapeutic Area Benchmark — Italy
Select a therapeutic area to compare against other sites in Italy.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Italy
Market Share
Country: Italy
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in ASST Grande Ospedale Metropolitano Niguarda
lock Showing 1 of 413 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| (21466) A multicenter, randomized, double-blind, placebo-controlled, Phase 3 study to investigate the efficacy, safety, and PK/ PD of finerenone, in addition to standard-of-care, in pediatric patients, 6 months to < 18 years of age, with heart failure (HF) and left ventricular systolic dysfunction (LVSD) | Bayer AG | Phase III | Recruiting | Jan 2026 | — |
IMP list
lock Showing 1 of 500 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Fluorouracil | 31 | Unknown | 2018-03-28 | 2026-07-20 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.
